CA2835819A1 - Induction of immune tolerance using methotrexate - Google Patents

Induction of immune tolerance using methotrexate Download PDF

Info

Publication number
CA2835819A1
CA2835819A1 CA2835819A CA2835819A CA2835819A1 CA 2835819 A1 CA2835819 A1 CA 2835819A1 CA 2835819 A CA2835819 A CA 2835819A CA 2835819 A CA2835819 A CA 2835819A CA 2835819 A1 CA2835819 A1 CA 2835819A1
Authority
CA
Canada
Prior art keywords
methotrexate
therapeutic
subject
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2835819A
Other languages
English (en)
French (fr)
Inventor
Alexandra JOSEPH
Susan Richards
Melanie Ruzek
Richard Garman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47177257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2835819(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CA2835819A1 publication Critical patent/CA2835819A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
CA2835819A 2011-05-16 2012-05-03 Induction of immune tolerance using methotrexate Abandoned CA2835819A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486697P 2011-05-16 2011-05-16
US61/486,697 2011-05-16
PCT/US2012/036405 WO2012158362A1 (en) 2011-05-16 2012-05-03 Induction of immune tolerance by using methotrexate

Publications (1)

Publication Number Publication Date
CA2835819A1 true CA2835819A1 (en) 2012-11-22

Family

ID=47177257

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2835819A Abandoned CA2835819A1 (en) 2011-05-16 2012-05-03 Induction of immune tolerance using methotrexate

Country Status (28)

Country Link
US (3) US20140135337A1 (enExample)
EP (2) EP2709627B1 (enExample)
JP (3) JP6174572B2 (enExample)
KR (3) KR102316283B1 (enExample)
CN (4) CN109620830A (enExample)
AU (1) AU2012256281B2 (enExample)
BR (1) BR112013029501A2 (enExample)
CA (1) CA2835819A1 (enExample)
CL (1) CL2013003298A1 (enExample)
CO (1) CO6841993A2 (enExample)
DO (1) DOP2013000268A (enExample)
EC (1) ECSP13013081A (enExample)
ES (1) ES2836823T3 (enExample)
GT (1) GT201300278A (enExample)
IL (2) IL229245B (enExample)
MA (1) MA35165B1 (enExample)
MX (1) MX2013013445A (enExample)
MY (1) MY173304A (enExample)
NI (1) NI201300121A (enExample)
PE (1) PE20140469A1 (enExample)
PH (1) PH12013502256A1 (enExample)
PT (1) PT2709627T (enExample)
RU (1) RU2674036C2 (enExample)
SG (1) SG194802A1 (enExample)
TN (1) TN2013000472A1 (enExample)
UA (1) UA117556C2 (enExample)
WO (1) WO2012158362A1 (enExample)
ZA (1) ZA201308315B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809282B2 (en) * 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
CN107320734A (zh) 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
AU2012256281B2 (en) 2011-05-16 2017-06-15 Genzyme Corporation Induction of immune tolerance by using methotrexate
CN105307641A (zh) * 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
ES2834129T3 (es) * 2013-06-04 2021-06-16 Selecta Biosciences Inc Administración repetida de agentes inmunoterapéuticos específicos de antígeno no inmunosupresores
EA201790551A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
JP2016213236A (ja) * 2015-04-30 2016-12-15 日東電工株式会社 半導体装置用フィルム、及び、半導体装置の製造方法
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018209300A1 (en) * 2017-05-12 2018-11-15 Duke University Methods for the use of low-dose immune modulators transiently for treating patients undergoing protein replacement therapy
TWI821227B (zh) * 2017-12-22 2023-11-11 美商健臻公司 胺甲喋呤誘發的免疫耐受性之生物標記
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
EP4100120A1 (en) 2020-02-08 2022-12-14 Genzyme Corporation Compositions and methods for treating pompe disease
CN117295948A (zh) * 2021-05-13 2023-12-26 建新公司 淋巴细胞清除疗法后的继发性自身免疫的新型预测性生物标记物
TW202342057A (zh) * 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080325A (en) 1976-11-17 1978-03-21 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of methotrexate
US4558690A (en) 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
US5108987A (en) 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
DE4000154A1 (de) 1990-01-04 1991-07-11 Symbiotec Gmbh Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
JP4927536B2 (ja) 2004-03-05 2012-05-09 電気化学工業株式会社 ヒアルロン酸−メトトレキサート結合体
US7884196B2 (en) 2004-10-06 2011-02-08 Oliver Lawless Vaccine composition comprising methylated DNA and immunomodulatory motifs
BRPI0708424A2 (pt) * 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
WO2008094937A2 (en) 2007-01-29 2008-08-07 Joslin Diabetes Center, Inc. Methods of modulating angiogenesis
WO2009073146A2 (en) * 2007-11-29 2009-06-11 Celgene Corporation Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) * 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
ES2632213T3 (es) 2008-10-08 2017-09-11 Cambridge Enterprise Limited Métodos y composiciones para diagnosticar y tratar una enfermedad autoinmunitaria que es secundaria con respecto a la esclerosis múltiple
KR20110093841A (ko) 2008-11-07 2011-08-18 4에스체 악티엔게젤샤프트 자가면역 질환의 치료를 위한 ｄｈｏｄｈ 억제제 및 메토트렉세이트를 포함하는 조합 요법
AU2012256281B2 (en) 2011-05-16 2017-06-15 Genzyme Corporation Induction of immune tolerance by using methotrexate

Also Published As

Publication number Publication date
IL276879B (en) 2022-06-01
TN2013000472A1 (en) 2015-03-30
CL2013003298A1 (es) 2014-07-25
IL229245A0 (en) 2014-01-30
EP3824890A1 (en) 2021-05-26
IL276879A (en) 2020-10-29
KR20140040744A (ko) 2014-04-03
GT201300278A (es) 2015-02-12
KR102316283B1 (ko) 2021-10-21
MA35165B1 (fr) 2014-06-02
IL229245B (en) 2020-08-31
JP2014513722A (ja) 2014-06-05
KR102163285B1 (ko) 2020-10-08
WO2012158362A1 (en) 2012-11-22
JP6174572B2 (ja) 2017-08-02
ECSP13013081A (es) 2015-04-30
PT2709627T (pt) 2020-12-24
US11672802B2 (en) 2023-06-13
DOP2013000268A (es) 2014-01-31
KR20190132551A (ko) 2019-11-27
PH12013502256A1 (en) 2022-04-08
JP6694020B2 (ja) 2020-05-13
US20140135337A1 (en) 2014-05-15
RU2013155618A (ru) 2015-06-27
BR112013029501A2 (pt) 2017-01-24
CN113209288A (zh) 2021-08-06
NZ617575A (en) 2016-10-28
MY173304A (en) 2020-01-14
NZ716716A (en) 2018-06-29
CN103648501A (zh) 2014-03-19
US20230372347A1 (en) 2023-11-23
NZ742216A (en) 2018-10-26
MX2013013445A (es) 2014-07-28
CN110124039A (zh) 2019-08-16
AU2012256281A1 (en) 2013-11-28
UA117556C2 (uk) 2018-08-27
EP2709627A1 (en) 2014-03-26
EP2709627B1 (en) 2020-09-23
JP2017141236A (ja) 2017-08-17
SG194802A1 (en) 2013-12-30
JP2018184466A (ja) 2018-11-22
EP2709627A4 (en) 2014-11-12
AU2012256281B2 (en) 2017-06-15
US20200360385A1 (en) 2020-11-19
PE20140469A1 (es) 2014-04-23
NI201300121A (es) 2014-02-28
CN109620830A (zh) 2019-04-16
JP6381707B2 (ja) 2018-08-29
ES2836823T3 (es) 2021-06-28
CO6841993A2 (es) 2014-01-20
RU2674036C2 (ru) 2018-12-04
ZA201308315B (en) 2014-07-30
KR20200116543A (ko) 2020-10-12

Similar Documents

Publication Publication Date Title
US20230372347A1 (en) Induction of immune tolerance by using methotrexate
Kishimoto Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies
Joly et al. Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa
Miura et al. TNX-1500, a crystallizable fragment–modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival
Warner et al. ABO-incompatible solid-organ transplantation
AU2003228829A1 (en) Induction of antigen specific immunologic tolerance
US20210236512A1 (en) Clozapine for the treatment of a immunoglobulin driven b cell disease
HK40053503A (en) Induction of immune tolerance using methotrexate
HK40053628A (en) Induction of immune tolerance by using methotrexate
NZ716716B2 (en) Induction of immune tolerance by using methotrexate
HK40012743A (en) Induction of immune tolerance by using methotrexate
OA16781A (en) Induction of immune tolerance by using methotrexate.
HK1194668B (en) Induction of immune tolerance by using methotrexate
HK1194668A (en) Induction of immune tolerance by using methotrexate
HK40007634A (en) Induction of immune tolerance by using methotrexate
NZ617575B2 (en) Induction of immune tolerance by using methotrexate
NZ742216B2 (en) Induction of immune tolerance by using methotrexate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170502

FZDE Discontinued

Effective date: 20220321